Carmell Therapeutics Valuation
| CTCX Stock | 0.53 0.04 7.02% |
Carmell Therapeutics is overvalued. Carmell Therapeutics shows a prevailing Real Value of USD0.49 per share. The current price of the firm is USD0.53. Our model approximates the value of Carmell Therapeutics from analyzing the firm fundamentals such as Operating Margin of (96.71) %, return on equity of -1.76, and Shares Outstanding of 30.12 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Carmell Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Carmell Therapeutics is based on 3 months time horizon. Increasing Carmell Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Carmell Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Carmell Stock. However, Carmell Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.53 | Real 0.49 | Hype 0.53 |
The intrinsic value of Carmell Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Carmell Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Carmell Therapeutics helps investors to forecast how Carmell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Carmell Therapeutics more accurately as focusing exclusively on Carmell Therapeutics' fundamentals will not take into account other important factors: Carmell Therapeutics Total Value Analysis
Carmell Therapeutics is currently forecasted to have valuation of 15.46 M with market capitalization of 15.82 M, debt of 2.14 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Carmell Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
15.46 M | 15.82 M | 2.14 M |
Carmell Therapeutics Asset Utilization
One of the ways to look at asset utilization of Carmell is to check how much profit was generated for every dollar of assets it reports. Carmell Therapeutics shows a negative utilization of assets of -0.85 percent, losing USD0.008464 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Carmell Therapeutics shows how discouraging it operates for each dollar spent on its assets.Carmell Therapeutics Ownership Allocation
Carmell Therapeutics holds a total of 30.12 Million outstanding shares. Carmell Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Carmell Therapeutics Profitability Analysis
Net Loss for the year was (15.45 M) with profit before overhead, payroll, taxes, and interest of 12.03 K.About Carmell Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Carmell Therapeutics. We calculate exposure to Carmell Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Carmell Therapeutics's related companies.Carmell Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 11 M | |
| Shares Float | 13 M |
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.